A selection of the news that emerged during the virtual conference.
The AAO held its first virtual meeting from Nov. 13 to 15. Below is a selection of the announcements that emanated from the conference.
Alcon presented clinical trial data on its AcrySof IQ Vivity IOL, which will launch soon in the United States. Vivity is a presbyopia-correcting IOL shown to improve intermediate and near vision compared to a monofocal IOL in those who had lens replacement surgery.
Bausch + Lomb showcased its SimplifEYE IOL delivery system, the first preloaded toric IOL available in the United States. The SimplifEYE is available exclusively for the enVista MX60PL and the enVista toric MX60PT and can be implanted in an eye through an incision as small as 2.2 mm.
EyeMD EMR Healthcare Systems Inc. debuted EyeMD EMR 2.0, which includes EMR, PM and PACS functionality. Other features include fully integrated billing and real-time claims management system as well as built-in clearing house and workflow automation functionality. EMR 2.0 uses fog-based computing technology, allowing practices system access from anywhere while also giving them the freedom of choosing the hosting architecture.
EyePoint Pharmaceuticals presented positive data of its YUTIQ and DEXYCU therapies at the virtual meeting. That data presented included: statistically significant efficacy results from the second Phase 3 trial of YUTIQ; data from a multicenter retrospective study of real-world usage of DEXYCU that demonstrated significant inflammatory reduction post-cataract surgery; and new data from an open-label study comparing a drug treatment regimen of DEXYCU with Prolensa to a full postoperative eyedrop treatment regimen that showed superior effects on inflammation, pain, visual acuity and patient preference in favor of the DEXYCU arm.
The AAO designated the Ivantis Hydrus Microstent as a “Level 1, Moderate Quality, Strong Recommendation” — the highest designation of any MIGS device — in its 2020 Preferred Practice Pattern (PPP) treatment guidelines. AAO’s PPPs are evidence-based recommendations designed to identify characteristics and components of quality eye care as guidance for the pattern of best practice.
Kala Pharmaceuticals presented educational activities at the meeting for EYSUVIS, recently approved by the FDA. EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% provides short-term treatment of the signs and symptoms of dry eye disease.
Nextech announced the release of IntelleChartPRO’s integrated, ophthalmology-specific ASC charting solution. It is designed to streamline clinical and ASC communications with an integrated, specialty-specific chart that increases efficiency and documentation accuracy while providing greater transparency of data.
Oyster Point Pharma announced data from its Phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray to treat the signs and symptoms of dry eye disease in adults. OC-01 nasal spray was found to be safe and well-tolerated in the study, with the most commonly reported treatment-related event being sneeze.
Santen presented posters on its MicroShunt (DE-128), an investigational surgical glaucoma implant to reduce designed to reduce IOP, as well as omidenepag isopropyl ophthalmic solution 0.002% (DE-117), an investigational topical ophthalmic solution for the treatment of elevated IOP.
Topcon released the Chronos automated binocular refraction system, with SightPilot-guided refraction software. The digital refractor combines autorefraction, keratometry and subjective refraction in a single device that occupies less than 4 feet of space.
Verana Health presented multiple studies at the AAO meeting. These included: New Insight into Real-World U.S. Anti-VEGF Injection Data, by Steven Schwartz, MD; Evaluation of Geographic Atrophy (GA) Secondary to AMD in Real-World Clinical Practice: Analysis of the AAO IRIS Registry, by Ehsan Rahimy, MD; and several on the effects of brolucizumab.
Zeiss presented its latest integrated diagnostic and surgical advances at the meeting, such as the VERACITY Surgical digital workflow software. VERACITY Surgical has been fully integrated with Zeiss devices such as the Central Topography and new Barrett True-K TK (non-toric and toric) formula of the IOLMaster 700, as well as automatic toric IOL implantation support functions of Callisto eye. OM
In the “What are the effective treatments for MGD patients” article in the December issue, two images were misidentified. Figure 1 showed the LipiFlow (J&J Vision) treatment, and Figure 3 displayed the TearCare (Sight Sciences) treatment. Ophthalmology Management regrets the error.